Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Dec 12, 2003
Webcast Alert: Executives from Aastrom Biosciences, BioCryst Pharmaceuticals, Dendreon, Genentech and Spectrum Pharmaceuticals Will Present at Informed Investors Biotech/Cancer Stocks Forum to be Webcast on Tuesday, December 16, 2003, 9 AM ET SAN FRANCISCO, Dec.
Dec 10, 2003
Spectrum Pharmaceuticals Bolsters Generic Capabilities With the Addition of Two Industry Veterans Two Have Contributed to Over 125 Regulatory Filings of Abbreviated New Drug Applications to the FDA and the Successful Launch of Multiple Generic Drugs IRVINE, Calif., Dec.
Dec 09, 2003
Spectrum Pharmaceuticals Appoints Shyam Kumaria, CPA, a Deloitte & Touche Veteran, as Vice President of Finance, to Head Spectrum's Finance Department Accomplished Financial Executive Brings Over 30 Years of Experience in Corporate Finance, Mergers and Acquisitions, and Operations Management
Dec 01, 2003
Spectrum Pharmaceuticals and FDC Ltd. Enter Into Generic Drug Marketing and Supply Agreement Agreement With Second Indian Pharmaceutical Manufacturer Marks Spectrum's Strategic Move Into Generic Eye Care Drugs IRVINE, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc.
Nov 24, 2003
Spectrum Pharmaceuticals Announces Nasdaq Decision to Continue Company's Smallcap Market Listing Listing Qualifications Panel rules that the Company has demonstrated continuing compliance with listing requirements and closes hearing file IRVINE, Calif., Nov.
Nov 21, 2003
Spectrum Pharmaceuticals to Present at the BioMilano 2003 Italian Partnering Conference IRVINE, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - ) announced its participation in the BioMilano 2003 Italian Partnering Conference in Milan, Italy today.
Nov 20, 2003
Spectrum Pharmaceuticals Announces Presentation of Clinical Data on EOquin(TM) at the American Association of Cancer Research-National Cancer Institute-European Organization for the Research and Treatment of Cancer (AACR-NCI-EORTC) Meeting in Boston Complete Disappearance of Tumors Reported by
Nov 17, 2003
Spectrum Pharmaceuticals Launches Phase 2 Study of EOquin(TM) in Bladder Cancer Monday November 17, 10:30 am ET Study to Be Conducted at up to 10 European Hospitals in Patients With Superficial Bladder Cancer IRVINE, CA--(MARKET WIRE)--Nov 17, 2003 -- Spectrum Pharmaceuticals, Inc.
Nov 14, 2003
Spectrum Pharmaceuticals Reports Third Quarter Financial Results IRVINE, CA--(MARKET WIRE)--Nov 14, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today reported a net loss for the third quarter ended September 30, 2003 of $2.7 million, or $(0.71) per share, compared to a net loss of $2.4
Nov 06, 2003
Spectrum Pharmaceuticals to Present at the 26th Annual Westergaard SmallCap Conference on November 11th Thursday November 6, 12:30 pm ET IRVINE, CA--(MARKET WIRE)--Nov 6, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today announced that it will present at the 26th annual Westergaard
Oct 17, 2003
Spectrum Pharmaceuticals Announces Change to Presentation Time at Rodman & Renshaw Techvest Healthcare Conference on October 22, 2003 Friday October 17, 8:00 am ET IRVINE, CA--(MARKET WIRE)--Oct 17, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI ) announced a change in the time of its
Oct 14, 2003
Spectrum Pharmaceuticals Announces Filing of ANDA for Carboplatin With the FDA Filing Marks Company's Strategic Move Into Anti-Cancer and Injectable Generic Products Tuesday October 14, 8:00 am ET IRVINE, CA--(MARKET WIRE)--Oct 14, 2003 -- Spectrum Pharmaceuticals, Inc.
Oct 13, 2003
Spectrum Pharmaceuticals Receives $2 Million From GPC Biotech on Launch of Phase 3 Registrational Trial of Satraplatin $25 Million of Cash on Hand to Fund Oncology Drug Development and Execute Strategic Plan Monday October 13, 8:00 am ET IRVINE, CA--(MARKET WIRE)--Oct 13, 2003 -- Spectrum
Sep 28, 2003
Spectrum Pharmaceuticals Completes $20 Million Financing With Institutional Investors Monday September 29, 12:01 am ET IRVINE,CA--(MARKET WIRE)--Sep 28, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today announced that it has raised $20 million through the sale of newly issued shares of
Sep 28, 2003
Spectrum Pharmaceuticals Announces Initiation of Phase 3 Registrational Trial of Satraplatin in Hormone-Refractory Prostate Cancer Monday September 29, 7:00 am ET IRVINE, CA--(MARKET WIRE)--Sep 29, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) and GPC Biotech AG (Frankfurt Stock Exchange:
Sep 22, 2003
Spectrum Pharmaceuticals Announces Fast Track Designation for Anticancer Drug Candidate Satraplatin From U.S. FDA Monday September 22, 7:00 am ET IRVINE, CA--(MARKET WIRE)--Sep 22, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:>SPPI) and GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30)
Sep 02, 2003
Spectrum Pharmaceuticals and GPC Biotech Receive Clearance From FDA to Initiate Phase 3 Registrational Trial of Satraplatin Primary Endpoint for Accelerated Approval Will Be Time to Disease Progression Tuesday September 2, 8:00 am ET IRVINE, CA--(MARKET WIRE)--Sep 2, 2003 -- Spectrum
Aug 18, 2003
Spectrum Pharmaceuticals and Lannett Company Announce Exclusive Supply and Distribution Agreement for Ciprofloxacin Monday August 18, 9:15 am ET IRVINE, CA--(MARKET WIRE)--Aug 18, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) and Lannett Company, Inc.
Aug 18, 2003
Spectrum Pharmaceuticals Reports Second Quarter Financial Results and Highlights Year-to-Date Progress Monday August 18, 9:00 am ET IRVINE, CA--(MARKET WIRE)--Aug 18, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today reported a net loss for the second quarter ended June 30, 2003 of $1.6
Aug 14, 2003
Spectrum Pharmaceuticals Completes $3 Million Financing Led by Baystar Capital Thursday August 14, 2:45 pm ET IRVINE, CA--(MARKET WIRE)--Aug 14, 2003 -- Spectrum Pharmaceuticals, Inc. (NasdaqSC:SPPI) today announced that it has raised approximately $3.0 million through the sale of newly issued
Displaying 721 - 740 of 773